Reduction in Pruritus Across Indications in Phase 3 Trials of Topical Roflumilast in Patients as Young as 2 Years. (2026). SKIN The Journal of Cutaneous Medicine, 10(2), s766. https://doi.org/10.25251/94s3pn30